ClinicalTrials.gg
CompletedNCT06535841Updated May 18, 2025

A First-in-Human Safety Trial of MTX-474

A Phase 1 interventional study of MTX-474 and Placebo in Healthy, sponsored by Mediar Therapeutics. Completed at 1 site in Australia. Open to participants aged 18 Years to 60 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-05-18.

Sponsored by Mediar Therapeutics · Phase 1, Interventional, and Other

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
78
Allocation
Randomized
Ages
18 Years to 60 Years
Sex
All
01

Study summary

A randomized, double-blind, placebo-controlled, single ascending dose (SAD) and multiple ascending dose (MAD) study to assess the safety, tolerability, and PK of single and multiple ascending doses of MTX-474 administered in healthy adults.

Read the detailed description

This is a randomized, double-blind, placebo-controlled, single ascending dose (SAD) and multiple ascending dose (MAD) study to assess the safety, tolerability, and PK of single and multiple ascending doses of MTX-474 administered in healthy adults.

SAD Portion

The SAD portion of the study will consist of 6 planned dosing cohorts each comprising 8 healthy participants. The starting dose will be 0.125 mg/kg (Cohort 1) with subsequent planned doses of 0.25 mg/kg (Cohort 2), 0.5 mg/kg (Cohort 3), 1 mg/kg (Cohort 4), 2 mg/kg (Cohort 5), and 4 mg/kg (Cohort 6). Planned doses may be adjusted in response to the data. Additional participants and/or additional dosing cohorts may be added as needed based on the data.

Within each cohort, participants will be randomly assigned to receive MTX-474 or matched placebo. The first 2 participants (sentinel participants) within each cohort will be randomized 1:1 to receive MTX-474 or placebo on Day 1. These participants will be monitored for 24 hours, and after review of the safety data from both participants and approval by the study Investigator, the additional 6 participants will be randomized to study drug (n=5 MTX-474; n=1 placebo).

Each participant will undergo assessments at specified timepoints on Days 1 through 29. End-of-Study (EOS) procedures will be completed on Day 29 or upon early termination (ET). An End-of-Follow-up (EOF) assessment of PK and ADA will be completed on Day 29.

MAD Portion

The MAD portion of the study will consist of 4 planned dosing cohorts. Each cohort will comprise 8 healthy participants (n=6 MTX-474; n=2 placebo). The starting dose will be 0.5 mg/kg (Cohort 1) with subsequent planned doses of 1 mg/kg (Cohort 2), 2 mg/kg (Cohort 3), and 4 mg/kg (Cohort 4). Planned doses may be adjusted in response to the data. Additional participants and/or additional dosing cohorts may be added as needed based on the data.

On Day 1, participants will be randomized to receive either MTX-474 or matched placebo. The randomized participants will receive a dose of study drug on Days 1, 8, 15, and 22. Participants will be housed inpatient from Day -1 through Day 2, Days 7 through 9, 14 through 16, and 21 through 23. All other visits will be conducted in the outpatient setting. Each participant will undergo assessments at specified timepoints on Days 1 through 50. End-of-study procedures will be completed on Day 50, or upon ET. An EOF assessment of PK and ADA will be completed on Day 50.

Safety and tolerability of MTX-474 will be reviewed through Day 29 by the study Investigator and SRMO to inform dose escalation decisions for the next dose cohort.

Additional cohorts for the SAD and MAD portions of the study may be added as needed to potentially explore alternative doses.

02

Conditions studied

  • Healthy

Keywords

  • MTX-474-S101
  • MTX-474
  • Healthy Volunteer
  • MAD
  • SAD
  • Adult
  • Healthy
03

In context

Lead sponsor

Mediar Therapeutics is the lead sponsor of 6 studies on the registry; 2 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 60 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • All genders, ages 18 to 60 years, inclusive
  • Willing and able to complete all protocol-required study visits and procedures
  • Consumption of not more than 5 cigarettes or other cotinine-containing products (including tobacco, nicotine gum, patches, and e-cigarettes) per week as long as they are willing to abstain nicotine use approximately 5 days prior to admission and during inpatient stays
  • Willing to refrain from marijuana- or cannabinol-containing products for 30 days before Screening and until the last study visit
  • Agree to a highly effective method of for 28 days prior to the first dose of study drug, and persist through 65 days after the last dose of study drug.

Exclusion criteria

Exclusion Criteria:

  • Any concurrent active medical condition determined by the Investigator
  • (BMI) >32 kg/m2 or body weight >100kg
  • Use of any systemic medications, medications to treat diabetes, antipsychotics, anticoagulants, or other medications within 90 days of Screening
  • Cancer or a history of cancer or lymphoproliferative disorder within 5 years of Screening other than adequately treated non-melanomatous skin cancers or cervical carcinoma in situ
  • Current infection with , , or (HIV) as evidenced by a positive hepatitis B surface antigen or a positive HIV test at Screening
  • Currently pregnant, lactating, or planning to conceive or contribute to pregnancy during the trial and up to 65 days (for women of ) or 125 days (for males) after the participant's last dose of study drug, if applicable
  • History of severe depression, psychosis, or suicidal ideation within 5 years of Screening
  • History of anaphylaxis or other significant allergies in the opinion of the Investigator
  • History of substance use disorder as specified in , Fifth Edition, within 1 year of Screening
  • Positive screen for drugs of abuse or alcohol intake at Screening or admission to the CRU (Day -1)
  • Any clinically significant disease or laboratory abnormality detected at Screening that might interfere with a participant's ability to complete the study, on-study evaluations, or participant safety
  • Any surgical procedure, including planned procedures within 12 weeks of Screening
  • Participation in another research study of an agent within 30 days of Screening or 5 half-lives of the agent, whichever is longer.
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 1
Primary purpose
Other
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
78 participants (actual)

Study arms

  • Experimental
    MTX-474

    Biological: MTX-474

    Biological: MTX-474

  • Placebo comparator
    Placebo

    Placebo

    Other: Placebo

Interventions

  • BiologicalMTX-474

    MTX-474 is an immunoglobin G1 (IgG1) monoclonal antibody directed against Ephrin B2 that binds to and has demonstrated ability to block phosphorylation of its preferred receptor EphB4. Increased levels of circulating soluble EphrinB2 have been found in patients with systemic sclerosis.

  • OtherPlacebo

    Matching Placebo - Normal Saline

06

What researchers measure

Primary outcomes

  1. Incidence of Treatment-Related Adverse Events in healthy volunteers

    Clinical Safety Labs are collected, and Adverse Events are assessed in both inpatient and outpatient clinic visits

    Time frame: Through Day 29 (SAD Cohort) or Day 50 (MAD Cohort)

  2. MTX-474 PK by dose will be evaluated for Cmax, as feasible

    Blood serum samples will be collected at protocol-specified timepoints throughout the study

    Time frame: Through Day 29 (SAD Cohort) or Day 50 (MAD Cohort)

  3. Serum sample results will be summarized for presence of Anti-Drug Antibodies during the SAD and MAD portions of the study

    Blood serum samples will be collected at protocol-specified timepoints throughout the study to assess for the presence and titer (if applicable) of Anti-Drug Antibodies.

    Time frame: Through Day 29 (SAD Cohort) or Day 50 (MAD Cohort)

  4. MTX-474 PK by dose will be evaluated for AUC0-t, as feasible

    Blood serum samples will be collected at protocol-specified timepoints throughout the study

    Time frame: Through Day 29 (SAD Cohort) or Day 50 (MAD Cohort)

  5. MTX-474 PK by dose will be evaluated for AUC0-tau (MAD only), as feasible

    Blood serum samples will be collected at protocol-specified timepoints throughout the study

    Time frame: Through Day 29 (SAD Cohort) or Day 50 (MAD Cohort)

  6. MTX-474 PK by dose will be evaluated for AUC0-∞, as feasible

    Blood serum samples will be collected at protocol-specified timepoints throughout the study

    Time frame: Through Day 29 (SAD Cohort) or Day 50 (MAD Cohort)

Secondary outcomes

  1. Blood serum samples will be collected to assess the target engagement of MTX-474 in healthy adult participants

    These assessments will be summarized as: Change from Baseline in bound EphrinB2 levels Change from Baseline in free EphrinB2 levels Change from Baseline in the percent phorphoEphB4 (pEpB4) positive cells and ratio of pEpB4 to total EphB4 positive cells

    Time frame: Through Day 29 (SAD Cohort) or Day 50 (MAD Cohort)

Other outcomes

  1. To assess the effect of MTX-474 on PD biomarker PRO-C3 for fibrosis in healthy adult participants

    Change from Baseline in fibrosis biomarker PRO-C3 will be evaluated.

    Time frame: Through Day 50 (MAD Cohort)

  2. To assess the effect of MTX-474 on PD biomarker PRO-C6 for fibrosis in healthy adult participants

    Change from Baseline in fibrosis biomarker PRO-C6 will be evaluated.

    Time frame: Through Day 50 (MAD Cohort)

  3. To assess the effect of MTX-474 on PD biomarker C7M for fibrosis in healthy adult participants

    Change from Baseline in fibrosis biomarker C7M will be evaluated.

    Time frame: Through Day 50 (MAD Cohort)

  4. To assess the effect of MTX-474 on PD biomarker PRO-C4 for fibrosis in healthy adult participants

    Change from Baseline in fibrosis biomarker PRO-C4 will be evaluated.

    Time frame: Through Day 50 (MAD Cohort)

  5. To assess the effect of MTX-474 on PD biomarker IFN-γ for inflammation in healthy adult participants

    Change from Baseline in pro-inflammatory biomarker IFN-γ will be evaluated.

    Time frame: Through Day 50 (MAD Cohort)

  6. To assess the effect of MTX-474 on PD biomarker IL-1β for inflammation in healthy adult participants

    Change from Baseline in pro-inflammatory biomarker IL-1β will be evaluated.

    Time frame: Through Day 50 (MAD Cohort)

  7. To assess the effect of MTX-474 on PD biomarker IL-2 for inflammation in healthy adult participants

    Change from Baseline in pro-inflammatory biomarker IL-2 will be evaluated.

    Time frame: Through Day 50 (MAD Cohort)

  8. To assess the effect of MTX-474 on PD biomarker IL-4 for inflammation in healthy adult participants

    Change from Baseline in pro-inflammatory biomarker IL-4 will be evaluated.

    Time frame: Through Day 50 (MAD Cohort)

  9. To assess the effect of MTX-474 on PD biomarker IL-6 for inflammation in healthy adult participants

    Change from Baseline in pro-inflammatory biomarker IL-6 will be evaluated.

    Time frame: Through Day 50 (MAD Cohort)

  10. To assess the effect of MTX-474 on PD biomarker IL-10 for inflammation in healthy adult participants

    Change from Baseline in pro-inflammatory biomarker IL-10 will be evaluated.

    Time frame: Through Day 50 (MAD Cohort)

  11. To assess the effect of MTX-474 on PD biomarker IL-12p70 for inflammation in healthy adult participants

    Change from Baseline in pro-inflammatory biomarker IL-12p70 will be evaluated.

    Time frame: Through Day 50 (MAD Cohort)

  12. To assess the effect of MTX-474 on PD biomarker IL-17A for inflammation in healthy adult participants

    Change from Baseline in pro-inflammatory biomarker IL-17A will be evaluated.

    Time frame: Through Day 50 (MAD Cohort)

  13. To assess the effect of MTX-474 on PD biomarker TNF-α for inflammation in healthy adult participants

    Change from Baseline in pro-inflammatory biomarker TNF-α will be evaluated.

    Time frame: Through Day 50 (MAD Cohort)

07

Study locations

1 site
  • Nucleus Network
    Herston, Queensland 4006, Australia
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jul 2024 to primary completion in Apr 2025, 9 months.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 30, 2024
First posted
Aug 2, 2024
StartActual
Jul 10, 2024
Primary completionActual
Apr 24, 2025
CompletionActual
Apr 24, 2025
Last update
May 18, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 18, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06535841
Lead sponsor
Mediar Therapeutics
Responsible party
Sponsor
First posted
Aug 2, 2024
Start date
Jul 10, 2024
Primary completion
Apr 24, 2025
Completion
Apr 24, 2025
Last update
May 18, 2025

Study contacts

Jeffrey Bornstein, MD
study director · Mediar Therapeutics
Gloria Wong, PhD, MBBS
principal investigator · Nucleus Network Brisbane

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion